natroxwoundcare.comCrawled Nov 12, 2026
Health Economics: Cost Effectiveness of Continuous Topical Oxygen Therapy for Unhealed Diabetic Foot Ulcers within the NHS presented at WOUNDS UK 2026.
NATROX O₂ Continuous Topical Oxygen Therapy delivers oxygen directly to wounds, increasing healing chances by 71% compared to standard care alone, according to evidence from VA medical centers.
NATROX O₂ is a wearable Continuous Topical Oxygen Therapy (cTOT) device clinically proven to heal chronic wounds including diabetic foot ulcers, venous leg ulcers, and pressure injuries — worn 24/7 at home.
Delphi participants agreed that topical oxygen therapy (TOT) should be prescribed for diabetic foot ulcers (DFUs) and supported payer reimbursement for this therapy.
NATROX Wound Care launched a video series demonstrating the application of its NATROX O₂ continuous topical oxygen therapy, requiring minimal training.
The Journal of Wound Care published a consensus on the evidence-based use of topical oxygen therapy (TOT) in chronic wound care, based on a review by international clinical experts.
The International Working Group on the Diabetic Foot (IWGDF) updated its guidelines to include topical oxygen therapy (TOT) as an adjunct treatment for diabetic foot ulcers (DFUs).
NATROX O₂ provides wound healing news, clinical evidence, and market updates.
The DME Medicare Administrative Contractors released a proposed Local Coverage Determination (LCD DL33797) for topical oxygen therapy (TOT), following a reconsideration process initiated in 2021.
Inotec AMD Ltd. was added as an approved supplier to the UK’s NHS Supply Chain for its continuous topical oxygen therapy.
NATROX Wound Care was named a 2026 HSBC Commercial Banking and WIRED Trailblazer for its innovation in oxygen-based wound therapy.
NATROX Wound Care promotes faster healing for chronic wound care patients worldwide.
International Sales Director
Director, Global Medical Affairs
Interim CEO
VP, U.S. Sales & Global Marketing
NATROX Wound Care was founded to promote faster healing for chronic wound care patients.
Fill out form.
NATROX O₂ Patient Help Center. Tips, tricks, and answers to frequently asked questions. Designed to empower patients.
NATROX Wound Care wins the 2026 HSBC-WIRED Trailblazer award for its oxygen-based wound therapy innovation. The company develops wearable devices delivering continuous topical oxygen to treat chronic wounds. This recognition highlights its role in advancing chronic wound care through novel medical technology.
Sep 2026NATROX® Wound Care | Innovative wound care technology that transforms livesNews article
Medicare has issued a proposed **Local Coverage Determination (LCD)** for **topical oxygen therapy**, outlining potential coverage criteria. The update targets wound care treatments using hyperbaric oxygen delivered directly to chronic or slow-healing wounds. Natrox Wound Care, a developer of topical oxygen devices, may be affected by the new guidelines.
Jul 2026NATROX® Wound Care | Innovative wound care technology that transforms livesNews article
Spartan Medical partners with NATROX Wound Care to expand access to **Continuous Topical Oxygen Therapy (cTOT)** in federal healthcare systems. The collaboration targets **U.S. Department of Veterans Affairs (VA), Department of Defense (DoD), and Indian Health Services (IHS)** facilities. NATROX develops advanced wound care solutions, while Spartan Medical supplies medical technologies to federal agencies.
Sep 2025NATROX® Wound Care | Innovative wound care technology that transforms livesNews article
Inotec AMD raises **$33 million in Series C funding** to expand its US operations. The company develops **NATRox O₂**, a leading continuous topical oxygen therapy for advanced wound care. Investors include Amadeus Capital Partners, Meltwind, Puhua Capital, and The Wealth Club. The funding supports Inotec’s global mission to treat chronic wounds and enhance patient outcomes.
Dec 2024NATROX® Wound Care | Innovative wound care technology that transforms livesNews article
